Cell-cell interactions drive many disease mechanisms, but are often overlooked in drug discovery.
Our HSC-deep learning platform interrogates these interactions at scale.
We’re developing therapeutic antibodies against these assays to create better treatments for diseases like colorectal cancer.
We’re leveraging computer vision and high-content screening to develop the next wave of therapeutic antibodies against cancer and fibrosis.
The assays we’ve developed allow us to screen interactions between multiple cell types at scale and the deep learning platform we’ve built allows us to efficiently analyze these more complex physiologically relevant disease models. We’re screening and developing our own therapeutic antibodies against these disease models with the goal of bringing ground-breaking drugs to the clinic for diseases like colorectal cancer.
With a state-of-the art pipeline for identifying and optimizing therapeutic antibodies against the phenotypic assays we’re developing, we’re now set to industrialize early stage discovery and maximize our opportunities in the clinic.
With a PhD from Brendan Frey's lab, Oren was one of the first researchers to apply deep learning to microscopy, publishing multiple times. He is right at the forefront of the deep learning revolution in biotechnology.
With expertise in molecular biology, oncology, machine learning, and even some practical synthetic chemistry knowledge, Sam is dedicated to realizing ideas that will change the world.
With over 8 years of industry experience in antibody discovery and pre-clinical development at Amgen and Northern Biologics, Arif is dedicated to driving Phenomic’s projects across the finish line.
Allison completed her PhD with Jason Moffat, a leader in biological drug discovery, where she developed some of the first potential therapeutic antibodies against mechanical signalling.
With five years of startup experience building products from scratch and time at Accenture developing deep learning solutions, Étienne is firmly in the elite deep learning developer camp.
Liz completed her PhD with Brad Wouter and before this designed and ran phenotypic assays for two years with a biotech start-up, Liz brings these awesome assay dev skills to Phenomic.
Max completed his PhD with Sachdev Sidhu, using phage display to target growth factor receptors with antibodies, that are now being spun out into patentable therapeutics.
Hayley completed her undergraduate at Waterloo after co-op placements at Apple and Deloitte. She now brings this big tech know-how to Phenomic.
Following an undergrad in C.S. from IIT Ropar, Kshitij travelled across the world to study machine learning in Toronto. Kshitij is working closely with partners on advanced segmentation problems.
Before making the leap to AI, Grant completed studies in theoretical physics at Waterloo and Boston University. Grant is now working at Phenomic AI with Jimmy Ba on unsupervised models.
“Learning unsupervised feature representations for single cell microscopy images with paired cell inpainting”
Alex Lu, Oren Kraus, Sam Cooper, Alan Moses